Eptifibatide Injection
Last Updated: August 11, 2016
Status: Current
Products Affected - Description
All presentations are currently available
Reason for the Shortage
- Merck states the reason for the shortage was manufacturing delay.
- AuroMedics launched eptifibatide injection in December 2015.
Available Products
Integrilin injection, Merck
0.75 mg/mL, 100 mL vial, 1 count (NDC 00085-1136-01)
2 mg/mL, 10 mL vial, 1 count (NDC 00085-1177-01)
2 mg/mL, 100 mL vial, 1 count (NDC 00085-1177-02)
Eptifibatide injection, AuroMedics
0.75 mg/mL, 100 mL vial, 1 count (NDC 55150-0218-99)
2 mg/mL, 10 mL vial, 1 count (NDC 55150-0219-10)
2 mg/mL, 100 mL vial, 1 count (NDC 55150-0220-99)
0.75 mg/mL, 100 mL vial, 1 count (NDC 55150-0218-99)
2 mg/mL, 10 mL vial, 1 count (NDC 55150-0219-10)
2 mg/mL, 100 mL vial, 1 count (NDC 55150-0220-99)
Estimated Resupply Dates
All marketed presentations are available.
Related Shortages
- Anagrelide Capsules — Resolved
- Cilostazol Tablets — Resolved
- Ticlopidine Tablets — No Longer Available
Updated
August 11, July 21, May 16, April 6, March 15, February 4, January 28, 2016; December 29, 22 and 1, October 28 and 8, September 23, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
